Hosted on MSN1mon
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy makerBluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million. Bluebird makes three gene therapies: Zynteglo for beta thalassemia, Lyfgenia for sickle cell ...
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $30 million, in a deal that lets the ...
Switzerland and GMOs In 2005, the Swiss people voted for a five-year ban on GMOs, which was then extended by parliament in 2010 until 2013 and once again in 2012 until 2017.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback